AlphAIAlphAI — Financial news for AI agents
scanx.trade$LQDA

Liquidia posts $236.3M loss on settlement; YUTREPIA sales up 31% QoQ

Liquidia Corporation reported a Q3 2026 net loss of $236.3M ($2.64 per share), missing estimates due to a $389.7M litigation settlement. Revenue grew 314% YoY to $225.3M, with YUTREPIA sales up 31% QoQ. Adjusted EBITDA was $140.5M. The company expects to fund settlement payments from cash and sales.

Original reporting
scanx.trade
Published Nov 10, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia posts $236.3M loss on settlement; YUTREPIA sales up 31% QoQ — source image
Source · scanx.trade
Decision brief

The 30-second read

$LQDABearishHigh
01

Why it matters

The settlement creates immediate downside risk for Liquidia but may improve long‑term outlook once litigation is resolved.

02

Market read

Primary disclosure of a large settlement drives short‑term negative sentiment for Liquidia; limited broader market impact.

03

What to watch

Strong revenue growth and positive adjusted EBITDA suggest underlying business strength.

Relevance 8/10Novelty 8/10Timing: post-market

Background

Liquidia's Q3 earnings miss stems from a one‑time legal settlement, while revenue and adjusted EBITDA remain robust.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Liquidia reported a $236.3M Q3 loss driven by a $389.7M litigation settlement charge.

Expected impact

downward pressure as market prices in the settlement charge

Evidence & confidence

The settlement is a large, one‑time expense that erodes earnings and cash, prompting sell‑offs.

$UTHRNeutralMedium confidence
Context

United Therapeutics entered a global settlement with Liquidia, paying $380.7M over 2026‑27.

Expected impact

limited effect; stock may stay flat or see slight upside if settlement resolves litigation risk

Evidence & confidence

The payment is spread over two years and does not affect United's core operations.

Market effects

Sector

Biotech sector may see heightened scrutiny of litigation risks.

Regional

US biotech stocks could face broader sell pressure.

Global

Limited; primarily affects US‑listed biotech investors.

Counterpoint

What could challenge this read

Some investors may view the settlement as clearing a hurdle, enabling future growth.

Key entities

  • company
    Liquidia Corporation

    Biotech firm reporting Q3 loss due to settlement.

  • company
    United Therapeutics Corporation

    Counterparty in the settlement agreement.

Read at source← All news

StoryLiquidia reports Q3 2026 loss driven by $389.7 M litigation settlement but revenue beats estimates

Also covered by

1 outlet

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K